Amylyx Pharmaceuticals (NASDAQ: AMLX) Soars on Positive Avexitide Clinical Trial Results

Font: Financial Modeling Prep  • Aug 18, 2026

• Amylyx Pharmaceuticals (NASDAQ: AMLX)'s drug candidate, avexitide, demonstrated positive Phase 3 clinical trial results, significantly reducing hypoglycemic events.
• An analyst from UBS Group AG (NYSE: UBS) set a $45.00 price target for Amylyx Pharmaceuticals, indicating a potential 36.01% increase, following a 54.43% stock surge.
• Strong investor interest is evident with Amylyx Pharmaceuticals' stock reaching a new $33.25 52-week high, boosting its market capitalization to approximately $3.68 billion with high trading volume.

Amylyx Pharmaceuticals (NASDAQ: AMLX) is a company that develops new treatments for severe diseases. It is currently gaining attention for its drug candidate, avexitide. This drug is an investigational treatment for post-bariatric hypoglycemia, a condition that can occur after certain weight-loss surgeries.

Following recent developments, an analyst from UBS Group AG (NYSE: UBS) sets a price target of $45.00 for Amylyx Pharmaceuticals. A price target is an analyst's projection of a stock's future price. With the stock trading at $33.09, this new target represents a potential increase of approximately 36.01% from its current level.

This analyst optimism comes after a major company announcement. Amylyx Pharmaceuticals reports positive results from its Phase 3 LUCIDITY clinical trial for avexitide. The study shows the drug reduces clinically significant hypoglycemic events by 55% compared to a placebo in certain adult patients.

The news causes a significant market reaction, as highlighted by Barrons. The stock price increases by $11.66, a 54.43% gain for the day, to reach $33.09. This trading activity pushes the stock to a new 52-week high of $33.25, well above its 52-week low of $7.63.

This price surge brings the company's market capitalization to approximately $3.68 billion. Market capitalization is the total value of all a company's shares of stock. Trading volume is also high, with over 17 million shares exchanged, indicating strong investor interest.